Last updated on August 2018

Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies

Brief description of study

The primary objective of this study is to characterize the safety, tolerability and maximum tolerated dose of BMS-986016 administered alone or in combination with Nivolumab to subjects with relapsed hematologic malignancies. Co-primary objective is to investigate the preliminary efficacy of BMS-986016 in combination with nivolumab in subjects with relapsed or refractory Hodgkin lymphoma (HL), and relapsed or refractory Diffuse Large B Cell lymphoma (DLBCL)

Clinical Study Identifier: NCT02061761

Contact Investigators or Research Sites near you

Start Over

Douglas Gladstone, Site 0007

The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD United States
  Connect »

Philippe Armand, Site 0004

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Asif Alavi, Site 0009

Barbara Ann Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Nancy Bartlett, Site 0010

Washington University School Of Medicine
Saint Louis, MO United States
  Connect »

John Leonard, Site 0003

Weill Cornell Medical College
New York, NY United States
  Connect »

Stephen Spurgeon, Site 0002

Oregon Health & Science University
Portland, OR United States
  Connect »

Sattva Neelapu, Site 0006

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Ajay Gopal, Site 0001

University of Washington
Seattle, WA United States
  Connect »

Kerry Savage, Site 0011

BC Cancer Agency - Vancouver Centre
Vancouver, BC Canada
  Connect »

John Kuruvilla, Site 0012

University Health Network - Princess Margaret Cancer Centre
Toronto, ON Canada
  Connect »